Teva’s Austedo guidance for 2025, at $1.9 billion to $2 billion, currently stands lower than Neurocrine's Ingrezza range. While “both brands are doing quite well,” according to Neurocrine ...
Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $1 EPS, expectations were $1.62. Operator: Good day, everyone, and ...
It's been a soft week for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares, which are down 19%. But we wouldn't complain about the gain over the last three years. In that time the stock gained 43 ...
Dr. Ratz joins Neurocrine after a 28-year career at Eli ... of more than 25 products across multiple therapeutic areas and molecule modalities. Most recently, he served as Lilly's Senior Vice ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback